Survival Analysis of Diabetic Colorectal Cancer Patients on Metformin
Metformin, an antihyperglycemic drug, has been associated with antineoplastic effects and could potentially improve colorectal cancer prognosis. The association between metformin and colorectal cancer prognosis has shown conflicting results. This study aims to define the association between metform...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
HH Publisher
2023-12-01
|
| Series: | Progress in Microbes and Molecular Biology |
| Online Access: | https://journals.hh-publisher.com/index.php/pmmb/article/view/919 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832541433570000896 |
|---|---|
| author | Alex Brandon Wong Ravi Patnaik Li Ling Chaw Shir Kiong Lu Long Chiau Ming Wen Han Chooi Ya Chee Lim |
| author_facet | Alex Brandon Wong Ravi Patnaik Li Ling Chaw Shir Kiong Lu Long Chiau Ming Wen Han Chooi Ya Chee Lim |
| author_sort | Alex Brandon Wong |
| collection | DOAJ |
| description |
Metformin, an antihyperglycemic drug, has been associated with antineoplastic effects and could potentially improve colorectal cancer prognosis. The association between metformin and colorectal cancer prognosis has shown conflicting results. This study aims to define the association between metformin and colorectal cancer prognosis in colorectal cancer patients in the Brunei population. The study was a retrospective cohort study that included colorectal cancer patients from The Brunei Cancer Center (TBCC) treated between July 2014 and July 2019. Kaplan-Meier and multivariate Cox proportional hazard regression models were used to analyze the data, construct survival curves, and adjust for comorbidities. Of a total of 112 diabetic patients, 79 patients (70.5%) were on metformin, and 33 patients (29.5%) were on other antihyperglycemic medications. An association between metformin use and lower incidence of stage IV colorectal cancer (p = 0.046) was observed, but no significant difference between the metformin group and the non-metformin group in terms of survival probability (log rank p = 0.13) was shown. Analysis using multivariate models showed that metformin reduces the hazard ratio by 31.2%, although this value is statistically insignificant (HR, 0.688; 95% CI 0.286 – 1.654; p = 0.403). Among the diabetic colorectal cancer patients, there was no association between survival and metformin therapy. However, the association between cancer progression and metformin use requires further investigation, and high-powered clinical trials are needed to support these findings.
|
| format | Article |
| id | doaj-art-b6b3df657d464d6e87a47910d7f71d58 |
| institution | Kabale University |
| issn | 2637-1049 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | HH Publisher |
| record_format | Article |
| series | Progress in Microbes and Molecular Biology |
| spelling | doaj-art-b6b3df657d464d6e87a47910d7f71d582025-02-04T08:39:44ZengHH PublisherProgress in Microbes and Molecular Biology2637-10492023-12-016110.36877/pmmb.a0000390Survival Analysis of Diabetic Colorectal Cancer Patients on MetforminAlex Brandon WongRavi PatnaikLi Ling ChawShir Kiong LuLong Chiau MingWen Han ChooiYa Chee Lim Metformin, an antihyperglycemic drug, has been associated with antineoplastic effects and could potentially improve colorectal cancer prognosis. The association between metformin and colorectal cancer prognosis has shown conflicting results. This study aims to define the association between metformin and colorectal cancer prognosis in colorectal cancer patients in the Brunei population. The study was a retrospective cohort study that included colorectal cancer patients from The Brunei Cancer Center (TBCC) treated between July 2014 and July 2019. Kaplan-Meier and multivariate Cox proportional hazard regression models were used to analyze the data, construct survival curves, and adjust for comorbidities. Of a total of 112 diabetic patients, 79 patients (70.5%) were on metformin, and 33 patients (29.5%) were on other antihyperglycemic medications. An association between metformin use and lower incidence of stage IV colorectal cancer (p = 0.046) was observed, but no significant difference between the metformin group and the non-metformin group in terms of survival probability (log rank p = 0.13) was shown. Analysis using multivariate models showed that metformin reduces the hazard ratio by 31.2%, although this value is statistically insignificant (HR, 0.688; 95% CI 0.286 – 1.654; p = 0.403). Among the diabetic colorectal cancer patients, there was no association between survival and metformin therapy. However, the association between cancer progression and metformin use requires further investigation, and high-powered clinical trials are needed to support these findings. https://journals.hh-publisher.com/index.php/pmmb/article/view/919 |
| spellingShingle | Alex Brandon Wong Ravi Patnaik Li Ling Chaw Shir Kiong Lu Long Chiau Ming Wen Han Chooi Ya Chee Lim Survival Analysis of Diabetic Colorectal Cancer Patients on Metformin Progress in Microbes and Molecular Biology |
| title | Survival Analysis of Diabetic Colorectal Cancer Patients on Metformin |
| title_full | Survival Analysis of Diabetic Colorectal Cancer Patients on Metformin |
| title_fullStr | Survival Analysis of Diabetic Colorectal Cancer Patients on Metformin |
| title_full_unstemmed | Survival Analysis of Diabetic Colorectal Cancer Patients on Metformin |
| title_short | Survival Analysis of Diabetic Colorectal Cancer Patients on Metformin |
| title_sort | survival analysis of diabetic colorectal cancer patients on metformin |
| url | https://journals.hh-publisher.com/index.php/pmmb/article/view/919 |
| work_keys_str_mv | AT alexbrandonwong survivalanalysisofdiabeticcolorectalcancerpatientsonmetformin AT ravipatnaik survivalanalysisofdiabeticcolorectalcancerpatientsonmetformin AT lilingchaw survivalanalysisofdiabeticcolorectalcancerpatientsonmetformin AT shirkionglu survivalanalysisofdiabeticcolorectalcancerpatientsonmetformin AT longchiauming survivalanalysisofdiabeticcolorectalcancerpatientsonmetformin AT wenhanchooi survivalanalysisofdiabeticcolorectalcancerpatientsonmetformin AT yacheelim survivalanalysisofdiabeticcolorectalcancerpatientsonmetformin |